Klexane (Enoxaparin Sodium)

Enoxaparin sodium binds to antithrombin III, markedly enhancing its inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This reduces thrombin generation and fibrin clot formation, providing anticoagulation with a predictable dose‑response relationship.

The dose of Klexane is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and any concurrent therapies. Only a qualified healthcare professional should determine the appropriate regimen.

Safety of enoxaparin sodium in pregnancy and lactation has not been fully established. It may be used only when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Klexane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Compared with unfractionated heparin, Klexane (enoxaparin) offers more predictable anticoagulant effects, a longer half‑life, and does not require routine laboratory monitoring in most patients. It also has a lower risk of heparin‑induced thrombocytopenia but is renally cleared, so dose adjustment may be needed in kidney impairment.

Klexane should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to less than 24 hours and keep the product in its original packaging.

Klexane is administered by subcutaneous injection, intravenous infusion, or through the haemodialysis circuit, depending on the clinical indication. Injection technique and site rotation are important to minimise local reactions, and infusion rates should follow the prescribing information.

The most serious risks include severe or uncontrolled bleeding, heparin‑induced thrombocytopenia (HIT), and spinal or epidural hematoma after neuraxial procedures. Patients should be monitored for signs of bleeding, sudden platelet count drops, or neurological symptoms, and therapy should be stopped immediately if these occur.

Klexane is contraindicated in patients with active major bleeding, severe thrombocytopenia, a known history of heparin‑induced thrombocytopenia, uncontrolled hypertension, or hypersensitivity to enoxaparin or any component of the formulation. Use in these populations should be avoided.